Pacific Bio to Acquire Omniome for $800 Million in Sequencing Tie-up
publication date: Aug 3, 2021
Pacific Biosciences, a San Francisco Bay area company offering long-read sequencing platforms, will acquire Omniome, a San Diego short-read company, for up to $800 million. With the acquisition, PacBio will be the only company to offer highly accurate long-read and short-read sequencing programs. PacBio said combining the two technologies will expand its market and provide more value to clients. Decheng Capital, a Shanghai venture firm, led Omniome's $60 million Series B and participated in its $60 million Series C financing. More details....
Stock Symbol: (NSDQ: PACB)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.